{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T19:59:55Z","timestamp":1700078395756},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1007\/s00292-005-0806-x","type":"journal-article","created":{"date-parts":[[2006,1,18]],"date-time":"2006-01-18T06:42:13Z","timestamp":1137566533000},"page":"40-46","source":"Crossref","is-referenced-by-count":4,"title":["H\u00e4matologische Nebenwirkungen der Tyrosinkinaseinhibition mit Imatinib"],"prefix":"10.1007","volume":"27","author":[{"given":"A.","family":"Schmitt-Graeff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"806_CR1","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1634\/stemcells.2005-0069","volume":"23","author":"Appel","year":"2005","unstructured":"Appel S, Balabanov S, Brummendorf TH, Brossart P (2005) Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells 23:1082\u20131088","journal-title":"Stem Cells"},{"key":"806_CR2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.leu.2403607","volume":"19","author":"Bacher","year":"2005","unstructured":"Bacher U, Hochhaus A, Berger U et al. (2005) Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha. Leukemia 19:460\u2013463","journal-title":"Leukemia"},{"key":"806_CR3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1196\/annals.1349.022","volume":"1044","author":"Balabanov","year":"2005","unstructured":"Balabanov S, Appel S, Kanz L et al. (2005) Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells. Ann N Y Acad Sci 1044:168\u2013177","journal-title":"Ann N Y Acad Sci"},{"key":"806_CR4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2003-05-1535","volume":"103","author":"Bartolovic","year":"2003","unstructured":"Bartolovic K, Balabanov S, Hartmann U et al. (2003) Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103:523\u2013529","journal-title":"Blood"},{"key":"806_CR5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood.V99.1.381","volume":"99","author":"Beham-Schmid","year":"2002","unstructured":"Beham-Schmid C, Apfelbeck U, Sill H et al. (2002) Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99:381\u2013383","journal-title":"Blood"},{"key":"806_CR6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V100.2.435","volume":"100","author":"Braziel","year":"2002","unstructured":"Braziel RM, Launder TM, Druker BJ et al. (2002) Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months\u2018 experience. Blood 100:435\u2013441","journal-title":"Blood"},{"key":"806_CR7","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","volume":"101","author":"Bumm","year":"2002","unstructured":"Bumm T, Muller C, Al-Ali HK et al. (2002) Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101:1941\u20131949","journal-title":"Blood"},{"key":"806_CR8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","volume":"55","author":"Deininger","year":"2003","unstructured":"Deininger MWN, Druker BJ (2003) Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55:401\u2013423","journal-title":"Pharmacol Rev"},{"key":"806_CR9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"Demetri","year":"2002","unstructured":"Demetri GD, Mehren M v, Blanke CD et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472\u2013478","journal-title":"N Engl J Med"},{"key":"806_CR10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.4161\/cc.4.7.1788","volume":"4","author":"Dewar","year":"2005","unstructured":"Dewar AL, Zannetino AC, Hughes TP, Lyons AB (2005) Inhibition of c-fms by imatinib. Cell Cycle 4:851\u2013853","journal-title":"Cell Cycle"},{"key":"806_CR11","doi-asserted-by":"crossref","unstructured":"Druker BJ, O\u2019Brien SG, Cortes J, Radich J (2002) Chronic myelogenous leukemia. Hematology 111\u2013135","DOI":"10.1182\/asheducation-2002.1.111"},{"key":"806_CR12","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/sj.leu.2403861","volume":"19","author":"Fabarius","year":"2005","unstructured":"Fabarius A, Giehl M, Frank O et al. (2005) Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 19:1573\u20131578","journal-title":"Leukemia"},{"key":"806_CR13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-005-1039-z","volume":"84","author":"Hehlmann","year":"2005","unstructured":"Hehlmann R, Berger U, Hochhaus A (2005) Chronic myeloid leukemia: a model for oncology. Ann Hematol 84:487\u2013497","journal-title":"Ann Hematol"},{"key":"806_CR14","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1055\/s-2004-831855","volume":"129","author":"Hochhaus","year":"2004","unstructured":"Hochhaus A, Berger U, Hehlmann R (2004) Therapy of chronic myelogeneous leukaemia in 2004. Dtsch Med Wochenschr 129:2122\u20132127","journal-title":"Dtsch Med Wochenschr"},{"key":"806_CR15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.hoc.2004.03.001","volume":"18","author":"Hochhaus","year":"2004","unstructured":"Hochhaus A, Hughes T (2004) Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 18:641\u2013656","journal-title":"Hematol Oncol Clin North Am"},{"key":"806_CR16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/1042819031000151905","volume":"45","author":"Holtz","year":"2004","unstructured":"Holtz MS, Bhatia R (2004) Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells. Leuk Lymphoma 45:237-45","journal-title":"Leuk Lymphoma"},{"key":"806_CR17","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","volume":"99","author":"Holtz","year":"2002","unstructured":"Holtz M, Slovak M, Zhang F et al. (2002) Gleevec (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99:3792\u20133800","journal-title":"Blood"},{"key":"806_CR18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/14740338.4.2.183","volume":"4","author":"Jones","year":"2005","unstructured":"Jones RL, Judson IR (2005) The development and application of imatinib. Expert Opin Drug Saf 4:183\u2013191","journal-title":"Expert Opin Drug Saf"},{"key":"806_CR19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00292-003-0677-y","volume":"25","author":"Kvasnicka","year":"2004","unstructured":"Kvasnicka HM, Thiele J, Staib P et al. (2004) Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia. Pathologe 25:127\u2013134","journal-title":"Pathologe"},{"key":"806_CR20","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","volume":"103","author":"Lahaye","year":"2005","unstructured":"Lahaye T, Riehm B, Berger U et al. (2005) Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 103:1659\u20131669","journal-title":"Cancer"},{"key":"806_CR21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/10428190500046778","volume":"46","author":"Lokeshwar","year":"2005","unstructured":"Lokeshwar N, Kumar L, Kumari M (2005) Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma 46:781\u2013784","journal-title":"Leuk Lymphoma"},{"key":"806_CR22","doi-asserted-by":"crossref","unstructured":"Melo JV, Hughes TP, Apperley JF (2003) Chronic myeloid leukemia. Hematology 132\u2013152","DOI":"10.1182\/asheducation-2003.1.132"},{"key":"806_CR23","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y et al. (2005) Dynamics of chronic myeloid leukaemia. Nature 435:1267\u20131270","journal-title":"Nature"},{"key":"806_CR24","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004","journal-title":"N Engl J Med"},{"key":"806_CR25","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood-2004-01-0246","volume":"104","author":"Pardanani","year":"2004","unstructured":"Pardanani A, Tefferi A (2004) Imatinib targets other than bcr\/abl and their clinical relevance in myeloid disorders. Blood 104:1931\u20131939","journal-title":"Blood"},{"key":"806_CR26","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0145-2126(03)00117-6","volume":"27","author":"Sacha","year":"2003","unstructured":"Sacha T, Hochhaus A, Hanfstein B et al. (2003) ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leuk Res 27:1163\u20131166","journal-title":"Leuk Res"},{"key":"806_CR27","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"Sawayers","year":"2002","unstructured":"Sawayers CL, Hochhaus A, Feldmann E et al. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530\u20133539","journal-title":"Blood"},{"key":"806_CR28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000085562","volume":"114","author":"Tefferi","year":"2005","unstructured":"Tefferi A (2005) Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 114:52\u201360","journal-title":"Acta Haematol"},{"key":"806_CR29","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","volume":"18","author":"Terre","year":"2004","unstructured":"Terre C, Eclache V, Rousselot P et al. (2004) Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 18:1340\u20131346","journal-title":"Leukemia"},{"key":"806_CR30","first-page":"1277","volume":"19","author":"Thiele","year":"2004","unstructured":"Thiele J, Kvasnicka HM, Schmitt-Graeff A et al. (2004) Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia. Histopathology 19:1277\u20131288","journal-title":"Histopathology"},{"key":"806_CR31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00292-004-0701-x","volume":"25","author":"Thiele","year":"2004","unstructured":"Thiele J, Kvasnicka HM, Varus E et al. (2004) Regression of the Philadelphia chromosome (bcr\/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML). Pathologe 25:428\u2013435","journal-title":"Pathologe"},{"key":"806_CR32","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/cncr.21419","volume":"104","author":"van der Zwan","year":"2005","unstructured":"van der Zwan SM, Dematteo RP (2005) Gastrointestinal stromal tumor: 5 years later. Cancer 104:1781\u20131788","journal-title":"Cancer"},{"key":"806_CR33","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J et al. (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127\u20131134","journal-title":"Lancet"},{"key":"806_CR34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009053765771","volume":"5","author":"Wiedmann","year":"2005","unstructured":"Wiedmann MW, Caca K (2005) Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 5:171\u2013193","journal-title":"Curr Cancer Drug Targets"},{"key":"806_CR35","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ejca.2005.04.034","volume":"41","author":"Zalcberg","year":"2005","unstructured":"Zalcberg JR, Verweij J, Casali PG et al. (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800\u00a0mg after progression on 400\u00a0mg. Eur J Cancer 41:1751\u20131757","journal-title":"Eur J Cancer"},{"key":"806_CR36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.bmt.1705087","volume":"36","author":"Zaucha","year":"2005","unstructured":"Zaucha JM, Prejzner W, Giebel S et al. (2005) Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 36:17\u201324","journal-title":"Bone Marrow Transplant"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-005-0806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00292-005-0806-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-005-0806-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:00:55Z","timestamp":1559041255000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00292-005-0806-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["806"],"URL":"https:\/\/doi.org\/10.1007\/s00292-005-0806-x","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}